IDEXX Laboratories, Inc. (IDXX) updated its 2025 EPS outlook range to $12.81 - $13.01, incorporating a $0.33 increase at midpoint from prior guidance, reflecting $0.22 benefit from operational performance, $0.04 benefit from lower effective tax rate, net of impacts related to recent U.S. tax law changes, and approximately $0.07 combined benefit from updated estimates for interest expense, average shares outstanding, and foreign exchange impacts. The updated EPS growth outlook is 20% - 22% as reported and 12% - 14% on a comparable basis.
The company updated full year revenue growth guidance range to $4.27 billion - $4.30 billion, or reported growth of 9.6% - 10.3%, an increase of $43 million at midpoint. The company increased outlook for organic revenue growth to 8.8% - 9.5%, an increase of approximately 1% at midpoint.
For the third quarter, The company's earnings totaled $274.61 million, or $3.40 per share. This compares with $232.84 million, or $2.80 per share, last year. Comparable EPS was $3.22 compared to $2.79. Analysts on average had expected the company to earn $3.14 per share. Analysts' estimates typically exclude special items. Revenue rose 13.3% to $1.105 billion from $975.54 million last year.
Shares of IDEXX are up 5% in pre-market trade on Monday.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.